W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma
TL;DR: The incremental cost-effectiveness ratio was within the established threshold that society is willing to pay (i.e., $50,000-$100,000), and sorafenib + BSC appears to be cost-effective in the management of advanced RCC.
Journal ArticleDOI
Adjuvant chemotherapy in lymph node positive bladder cancer
Ofer N. Gofrit,Walter M. Stadler,Kevin C. Zorn,Shang Lin,Josephine Silvestre,Arieh L. Shalhav,Gregory P. Zagaja,Gary D. Steinberg +7 more
TL;DR: This study supports the use of adjuvant chemotherapy after radical cystectomy in patients with node positive bladder cancer, and concludes that the design and patient imbalances make it impossible to draw definitive conclusions.
Journal ArticleDOI
Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).
Andrew J. Armstrong,Samuel Broderick,Tim Eisen,Walter M. Stadler,Robert Jones,Jorge A. Garcia,Ulka N. Vaishampayan,Joel Picus,Robert E. Hawkins,John D. Hainsworth,Christian K. Kollmannsberger,Theodore F. Logan,Igor Puzanov,Lisa Pickering,Christopher W. Ryan,Andrew Protheroe,Christine M. Lusk,Sadie Oberg,Susan Halabi,Daniel J. George +19 more
TL;DR: A large number of patients with metastatic non-clear cell RCC are diagnosed with atypical central giant cell granuloma and the decision to treat them with chemotherapy or radiation is made based on prior treatment regimens.
Journal ArticleDOI
A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer.
Everett E. Vokes,Francis P. Worden,Douglas Adkins,Julie E. Bauman,Dean Lim,Ammar Sukari,Krishna Rao,Stephanie Ann Wagner,Kelly K. Curtis,Barbara J. Gitlitz,Katharine A. Price,James L. Wade,Victoria M. Villaflor,Jonas A. De Souza,Theodore Karrison,Walter M. Stadler,Tanguy Y. Seiwert +16 more
TL;DR: This data indicates that MET signaling has been proposed as a mechanism of resistance to anti-EGFR therapy and is common in Head and Neck Squamous Cell Carcinomas.
Journal ArticleDOI
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
Thomas Powles,Michael B. Atkins,Bernard Escudier,Robert J. Motzer,Brian I. Rini,Lawrence Fong,Richard W. Joseph,Sumanta K. Pal,Mario Sznol,John D. Hainsworth,Walter M. Stadler,Thomas E. Hutson,Alain Ravaud,Sergio Bracarda,Cristina Suarez,Toni K. Choueiri,James A. Reeves,Allen Lee Cohn,Beiying Ding,Ning Leng,Kenji Hashimoto,Mahrukh Huseni,Christina Schiff,David F. McDermott +23 more
TL;DR: In this paper, the authors evaluated the efficacy and safety of atezolizumab+bevacizumaba using a randomized, open-label, phase 2 study with metastatic clear cell renal cancer (mRCC).